SCHEDULE: Adage Capital Discloses 3.15% Stake in Ensysce

Adage Capital Management and its principals have disclosed a 3.15% passive beneficial ownership stake in Ensysce Biosciences, Inc.

Summary

• Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively hold beneficial ownership of 74,711 shares of Ensysce Biosciences, Inc. Common Stock.
• This ownership represents 3.15% of the company's outstanding Common Stock.
• The percentage is calculated based on 2,370,698 shares of Common Stock outstanding as of May 8, 2025, as reported in Ensysce Biosciences, Inc.'s Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The reporting persons have shared voting power and shared dispositive power over all 74,711 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment position.

Sentiment

Score: 5

Explanation: This filing is a routine disclosure of passive beneficial ownership and does not contain performance or strategic updates that would significantly alter sentiment.

Positives

• The disclosure indicates an investment by Adage Capital Management, L.P., a notable investment manager, which may signal confidence in Ensysce Biosciences, Inc.

Risks

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, indicating a passive investment approach.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes in the company.

Key Dates

Keywords

Ensysce Biosciences, Adage Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment, SEC Filing, Passive Stake